<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>45-CALCIUM-CHANNEL-BLOCKERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="CALCIUM CHANNEL BLOCKERS" code="CO8CA-001" /></DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism

</DESCRIPTION>
<SEVERITY>Not recommended:</SEVERITY>
<COMMENT>with the nimodipine</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>45-CALCIUM-CHANNEL-BLOCKERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="CALCIUM CHANNEL BLOCKERS" code="CO8CA-001" /></DRUG1>
<DRUG2>
<DRUG name="IDELALISIB " rxcui="1544460">
<ATC code="L01XX47" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the undesirable effects of the calcium channel blockers, of the orthostatic hypotension sort, especially with older patients</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of the calcium channel blocker during the treatment with idelalisib and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>45-CALCIUM-CHANNEL-BLOCKERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="CALCIUM CHANNEL BLOCKERS" code="CO8CA-001" /></DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase of the undesirable effects of the calcium channel blockers, most often of the hypotension type, especially in older patients.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and dosage adjustment during the treatment with the enzymatic inhibitor and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>45-CALCIUM-CHANNEL-BLOCKERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="CALCIUM CHANNEL BLOCKERS" code="CO8CA-001" /></DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="">
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>with the nimodipine</COMMENT>
</INTERACTION>
</INTERACTIONS>
